AbbVie 4Q Sales Lower as Humira Revenue Sinks
By Dean Seal
AbbVie posted lower revenue in the fourth quarter following a drop in sales for its blockbuster therapy Humira, but the top line still beat analyst estimates with growth from other drugs in its immunology portfolio.
The drugmaker recorded a profit of $822 million, or 46 cents a share, compared with $2.47 billion, or $1.38 a share, in the same quarter a year ago.
AbbVie's adjusted earnings of $2.79 a share were in line with the expectations of analysts polled by FactSet.
Revenue slid to $14.3 billion from $15.12 billion in last year's fourth quarter, above analyst forecasts for $14.02 billion, according to FactSet.
Revenue from its immune-disease therapy Humira, which is facing biosimilar competition, fell 41% to $3.3 billion, while sales of its arthritis drugs Skyrizi and Rinvoq were up 52% and 63%, respectively.
Abbvie expects to post adjusted earnings of $11.05 to $11.25 in 2024, which includes a 32 cent per-share dilutive impact from the proposed acquisitions of ImmunoGen and Cerevel Therapeutics, which are expected to close in the middle of the new year.
The North Chicago, Ill.-based company is also lifting its long-term outlook for Skyrizi and Rinvoq, saying it now expects revenue of $27 billion from the drugs in 2027 instead of $21 billion as it had previously projected.
Write to Dean Seal at dean.seal@wsj.com
Corrections & Amplifications
This headline was corrected at 8:35 a.m. ET because the name of the drug Humira was misspelled as Himura.
This item was corrected at 10:20 a.m. ET to show that AbbVie's adjusted earnings of $2.79 a share were in line with the expectations of analysts polled by FactSet. An earlier version compared the adjusted earnings result to FactSet's original consensus estimate of $2.80 a share, which has been updated to $2.79.
(END) Dow Jones Newswires
February 02, 2024 08:20 ET (13:20 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
5 Stocks to Buy That We Still Like After They’ve Run Up
-
Markets Brief: Stocks Are Starting to Look Cheap Again
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track
-
American Airlines Earnings: We See Costs Overshadowing Market Share This Year
-
Snap Earnings: Advertising Growth and Snapchat+ Drive Monetization
-
STMicro Earnings: We Still See an Attractive Margin of Safety Despite a Poor First-Half Forecast
-
Alphabet Shares Surge on Strong Earnings, Dividend Surprise
-
Microsoft Earnings: Firm Beats Forecasts on Strong AI and Cloud Demand
-
PG&E Earnings: Near-Term Regulatory Certainty Supports Industry-Leading Earnings Growth